Core Viewpoint - 康希诺 reported a significant increase in revenue and a return to profitability in the first three quarters of 2025, driven by strong market performance of its innovative vaccine products and enhanced government support [1] Financial Performance - The company achieved an operating income of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to the company was 14.44 million yuan, marking a turnaround from previous losses [1] Product and Market Development - 曼海欣, as one of the only four-valent meningococcal conjugate vaccines in China, has shown strong market performance and increasing market share [1] - The growth in sales revenue contributed to the year-on-year increase in operating income from the beginning of the year to the reporting period [1] Research and Development Support - The company has accelerated its R&D projects and international collaborations, leading to increased government grants and international funding, resulting in a year-on-year increase of 233.63% in recognized other income [1] Profitability and Cost Management - The overall gross profit margin for the reporting period was 80.67%, an increase of 6.47 percentage points year-on-year [1] - The company has implemented cost reduction and efficiency improvement measures, achieving savings in multiple expense categories during the reporting period [1]

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 董事會提名委員會工作細則 第一章 總 則 第一條 為 規 範 康 希 諾 生 物 股 份 公 司（以 下 簡 稱「公 司」）董 事 及 高 級 管 理 人 員 的 產 生，優 化 董 事 會 組 成，完 善 公 司 治 理 結 構，根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公司法》」）《上 海 證 券 交 易 所 科 創 板 股 票 上 市 規 則》（以 下 簡 稱「《科創板上 市規則》」）《上 海 證 券 交 易 所 科 創 板 上 市 公 司 自 律 監 管 指 引 第1號––規 範 運 作》（以 下 簡 稱「《科創板規範運作》」）《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下 簡 稱「《香港上市規則》」）等 相 關 法 律、法 規、規 範 性 文 件 及《康 希 諾 生 物 股 份 公 司 章 程》（以 下 簡 稱「《公司章程》」），公 司 特 設 立 董 事 會 提 名 委 員 會，並 結 合 公 司 實 際， 制 定 本《康 希 諾 ...

Core Viewpoint - 康希诺生物 reported a significant improvement in financial performance for the first three quarters of 2025, with a notable increase in revenue and a shift from loss to profit [1] Financial Performance - The company achieved an operating revenue of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to shareholders was 14.44 million yuan, a turnaround from a net loss of 222 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.06 yuan [1]

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 董事會審計委員會工作細則 第一章 總 則 第一條 為 強 化 康 希 諾 生 物 股 份 公 司（以 下 簡 稱「公 司」）董 事 會 決 策 功 能，持 續 完 善公司內部控制體系建設，確保董事會的有效監督管理，不斷完善公司治理結構， 根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公司法》」）《上 海 證 券 交 易 所 科 創 板 股 票 上 市 規 則》（以 下 簡 稱「《科創板上市規則》」）《上 海 證 券 交 易 所 科 創 板 上 市 公 司 自律監管指引第1號－規 範 運 作》（以 下 簡 稱「《科創板規範運作》」）《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下 簡 稱「《香港上市規則》」）、香 港 會 計 師 公 會《審 計 委 員 會 有 效 運 作 指 引》等 相 關 法 律、法 規、規 範 性 文 件 及 現 行 適 用 的《康 希 諾 生 物 股 份 公 司 章 程》（以 下 簡 稱「《公司章程》」），公 司 特 設 立 董 ...

康希诺生物(06185)发布公告，桂水发先生及刘建忠先生已提呈辞任独立非执行董事。辞任原因为其担 任独立非执行董事的六年任期即将届满。此外，左敏先生及纪雪峰女士已获提名为第三届董事会独立非 执行董事候选人，但须经股东于临时股东大会上批准。 ...

格隆汇10月27日丨康希诺生物(06185.HK)宣布，桂水发及刘建忠已提呈辞任独立非执行董事。辞任原因 为其担任独立非执行董事的六年任期即将届满。 同时宣布，左敏及纪雪峰女士已获提名为第三届董事会独立非执行董事候选人，惟须经股东于临时股东 大会上批准。 ...

智通财经APP讯，康希诺生物(06185)发布公告，桂水发先生及刘建忠先生已提呈辞任独立非执行董事。 辞任原因为其担任独立非执行董事的六年任期即将届满。此外，左敏先生及纪雪峰女士已获提名为第三 届董事会独立非执行董事候选人，但须经股东于临时股东大会上批准。 ...

Group 1 - Northern Rare Earth reported a net profit increase of 280% year-on-year for the first three quarters, driven by higher sales volume and prices of rare earth products [1] - Postal Savings Bank has received approval to establish a financial asset investment company with a registered capital of 10 billion yuan, aimed at enhancing comprehensive service capabilities and supporting technological innovation [2] - Silyus announced a maximum price of HKD 131.5 per share for its H-share issuance, with a total of 100.2 million shares available for global offering [3] Group 2 - Hengtong Optic-Electric won a bid for marine energy projects with a total contract value of 1.868 billion yuan, including the supply and construction of undersea cables [4] - Western Mining's subsidiary Yulong Copper won exploration rights for the Chating copper polymetallic mine for 8.609 billion yuan, which is expected to enhance the company's resource reserves [5] - China Bank appointed Liu Chenggang as vice president, effective from October 24, 2025 [6] Group 3 - ST Guangwu announced the removal of other risk warnings for its stock, changing its name to Guanghui Logistics, which will allow for a wider trading limit [7] - Wireless Media set an initial transfer price of 29.11 yuan per share for its inquiry transfer, with a subscription multiple of 2.01 times [8][9] - Jiangshan Oupai's subsidiaries in Henan and Chongqing will cease operations due to insufficient orders, with business transferred to its Zhejiang base [10] Group 4 - Zhenyu Technology plans to invest 2.11 billion yuan in precision component manufacturing and humanoid robot projects, with the first phase of investment to be signed soon [11] - Jinyuan Co. announced the resignation of its general manager, with Qiu Yongping appointed as the new general manager [12] Group 5 - CanSino reported a net profit of 27.93 million yuan for Q3, a year-on-year increase of 842.01% [13] - Jiangshan Co. reported a net profit of 86.73 million yuan for Q3, a year-on-year increase of 11,890.01% [14] - Yingshi Innovation reported a net profit of 272 million yuan for Q3, a year-on-year decrease of 15.90% [15] Group 6 - Chip Origin reported a net loss of 26.85 million yuan for Q3, despite a revenue increase of 78.38% [16] - Tonghua Dongbao reported a net profit of 984 million yuan for Q3, a year-on-year increase of 499.86% [17] - Hengrui Medicine reported a net profit of 1.301 billion yuan for Q3, a year-on-year increase of 9.53% [18] Group 7 - Zhongguang Lightning reported a net profit of 6.46 million yuan for Q3, a year-on-year increase of 382.66% [19] - Ice River Network reported a net profit of 166 million yuan for Q3, a year-on-year increase of 244.58% [20] - Daheng Technology reported a net profit of 71.48 million yuan for Q3, a year-on-year increase of 1,960.72% [21] Group 8 - Yanjin Puzhi reported a net profit of 232 million yuan for Q3, a year-on-year increase of 33.55% [22] - Sichuan Gold reported a net profit of 160 million yuan for Q3, a year-on-year increase of 184.38% [23] - Sanbo Brain Science reported a net profit of 13.93 million yuan for Q3, a year-on-year decrease of 63.26% [24] Group 9 - Hengli Petrochemical reported a net profit of 1.972 billion yuan for Q3, a year-on-year increase of 81.47% [25] - Deepin Technology reported a net profit of 147 million yuan for Q3, a year-on-year increase of 1,097.40% [26] - Huisheng Biological reported a net profit of 70.72 million yuan for Q3, a year-on-year increase of 1,575.79% [27] Group 10 - Gaode Infrared reported a net profit of 401 million yuan for Q3, a year-on-year increase of 1,143.72% [28] - Qingdao Beer reported a net profit of 1.37 billion yuan for Q3, a year-on-year increase of 1.62% [29] - Nanjing Public Utilities reported a net profit of 84.62 million yuan for Q3, a year-on-year increase of 2,492.12% [30] Group 11 - Zhangyuan Tungsten reported a net profit of 75.02 million yuan for Q3, a year-on-year increase of 118.56% [31] - Yongmaotai reported a net profit of 30.41 million yuan for Q3, a year-on-year increase of 6,319.92% [32] Group 12 - Tongrun Equipment announced that two shareholders plan to reduce their holdings by 1.50% each, totaling a maximum of 3.00% [33] - High-speed Rail Electric announced a pre-bid for a city rail transit project worth 62.39 million yuan [34]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） (1)建議取消監事會 及建議修訂公司章程及議事規則 (2)建議修訂企業管治規則 (3)董事辭任 (4)建議委任獨立非執行董事 康希諾生物股份公司（「本公司」）於2025年10月27日舉行第三屆董事（「董事」）會（「董 事會」）第九次會議，以審議及批准（其中包括）(i)建議取消本公司監事會（「監事會」） 及 建 議 修 訂 本 公 司 公 司 章 程（「公司章程」）及 本 公 司 股 東（「股 東」）大 會 議 事 規 則 及 董 事 會 議 事 規 則（統 稱「議事規則」）；(ii)建議修訂若干企業管治規則；及(iii)建 議 委任獨立非執行董事。 建議取消監事會及建議修訂公司章程及議事規則 董事會謹此宣佈，於2025年10月27日，董 事 會 經 審 議 及 批 准（其 ...

Financial Performance - Total revenue for the reporting period reached RMB 310,238,146.22, representing a year-on-year increase of 17.67%[6] - Net profit attributable to shareholders was RMB 27,925,556.13, showing an impressive increase of 842.01% compared to the same period last year[6] - Basic and diluted earnings per share were both RMB 0.11, reflecting a significant increase of 1,000% from RMB 0.06 in the previous year[7] - The total profit for the period was RMB 27,790,806.52, a remarkable increase of 695.73% compared to the same period last year[6] - The total profit for the reporting period reached RMB 842.01 million, representing a year-on-year increase of 695.73%[13] - The net profit attributable to shareholders for the reporting period was RMB 27.93 million, with a significant year-on-year increase[14] - Other income recognized during the reporting period amounted to RMB 91.60 million, reflecting a year-on-year growth of 233.63%[13] - The comprehensive gross profit margin for the reporting period was 80.67%, an increase of 6.47 percentage points year-on-year[17] Research and Development - Research and development expenses totaled RMB 90,547,462.82, a decrease of 16.10% year-on-year, accounting for 29.19% of total revenue, down 11.74 percentage points[7] - Research and development expenses for the first three quarters of 2025 amounted to ¥224,666,107.48, down from ¥272,272,224.71 in 2024, reflecting a decrease of approximately 17.5%[35] Cash Flow and Operating Activities - The company reported a net cash flow from operating activities of RMB 33,494,897.39 for the reporting period[6] - The net cash flow from operating activities for the reporting period was RMB 22.22 million, reversing from a net outflow in the previous year[18] - The net cash flow from operating activities for the year-to-date period was RMB 33.49 million, also showing a reversal from the previous year's outflow[18] - Cash flow from operating activities generated a net cash inflow of ¥33,494,897.39 in the first three quarters of 2025, compared to a net cash outflow of ¥287,414,483.35 in the same period of 2024[42] Assets and Liabilities - Total assets at the end of the reporting period were RMB 7,301,190,997.13, a decrease of 8.25% from the previous year[7] - The company's total assets as of September 30, 2025, were ¥7,301,190,997.13, a decrease from ¥7,958,132,235.38 at the end of 2024[30] - Current assets totaled ¥3,939,112,041.80 as of September 30, 2025, down from ¥4,282,490,715.65 at the end of 2024, representing a decline of about 8.0%[29] - Total liabilities decreased to ¥2,369,829,747.59 as of September 30, 2025, from ¥3,048,260,581.65 at the end of 2024, indicating a reduction of approximately 22.3%[31] Equity and Shareholder Information - The return on equity increased to 0.57%, up 0.51 percentage points from the previous year[7] - The total equity attributable to shareholders was ¥4,931,361,249.54 as of September 30, 2025, up from ¥4,909,871,653.73 at the end of 2024, showing a slight increase of approximately 0.4%[32] - The company reported a net loss of ¥(1,922,857,713.42) for the equity attributable to shareholders as of September 30, 2025, compared to a loss of ¥(1,937,297,858.98) at the end of 2024, indicating a slight improvement[32] Operational Efficiency - The company achieved a significant improvement in operational efficiency through resource integration[14] - The company continues to enhance its accounts receivable management, leading to improved cash collection in its vaccine-related business[18] Future Outlook - The company will implement new accounting standards starting from 2025, which may affect the financial statements[44]